Clinical trial · no report yet · Phase 3
KEYNOTE D46
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- NCT05609968 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Sacituzumab Govitecan; Pembrolizumab
- Arms
- Pembrolizumab + Sacituzumab Govitecan · Experimental
- Pembrolizumab · Experimental
- Enrollment
- 614 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC with Gilead Sciences
- Start
- Feb 6, 2023
- Primary completion
- Jan 12, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05609968 · updated Dec 24, 2025